178 related articles for article (PubMed ID: 29344308)
1. "Albumin Hitchhiking" with an Evans Blue Analog for Cancer Theranostics.
Ehlerding EB; Lan X; Cai W
Theranostics; 2018; 8(3):812-814. PubMed ID: 29344308
[TBL] [Abstract][Full Text] [Related]
2. Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy.
Tian R; Jacobson O; Niu G; Kiesewetter DO; Wang Z; Zhu G; Ma Y; Liu G; Chen X
Theranostics; 2018; 8(3):735-745. PubMed ID: 29344302
[No Abstract] [Full Text] [Related]
3. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
4. Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent.
Bandara N; Jacobson O; Mpoy C; Chen X; Rogers BE
Bioconjug Chem; 2018 Jul; 29(7):2448-2454. PubMed ID: 29927587
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
7. The Search for an Alternative to [
Waldmann CM; Stuparu AD; van Dam RM; Slavik R
Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834
[TBL] [Abstract][Full Text] [Related]
8. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
9. Intraindividual comparison of [
Hänscheid H; Hartrampf PE; Schirbel A; Buck AK; Lapa C
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2566-2572. PubMed ID: 33452632
[TBL] [Abstract][Full Text] [Related]
10. Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model.
Ullrich M; Bergmann R; Peitzsch M; Zenker EF; Cartellieri M; Bachmann M; Ehrhart-Bornstein M; Block NL; Schally AV; Eisenhofer G; Bornstein SR; Pietzsch J; Ziegler CG
Theranostics; 2016; 6(5):650-65. PubMed ID: 27022413
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models.
Ullrich M; Richter S; Liers J; Drukewitz S; Friedemann M; Kotzerke J; Ziegler CG; Nölting S; Kopka K; Pietzsch J
Theranostics; 2023; 13(1):278-294. PubMed ID: 36593963
[TBL] [Abstract][Full Text] [Related]
12. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
13.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin Receptor Antagonists for Imaging and Therapy.
Fani M; Nicolas GP; Wild D
J Nucl Med; 2017 Sep; 58(Suppl 2):61S-66S. PubMed ID: 28864614
[TBL] [Abstract][Full Text] [Related]
15. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
[TBL] [Abstract][Full Text] [Related]
16. Theranostic in Nuclear Medicine - The paradigm of NET.
Giammarile F
Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
[TBL] [Abstract][Full Text] [Related]
17. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
[TBL] [Abstract][Full Text] [Related]
18. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.
Seregni E; Maccauro M; Coliva A; Castellani MR; Bajetta E; Aliberti G; Vellani C; Chiesa C; Martinetti A; Bogni A; Bombardieri E
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):84-91. PubMed ID: 20168290
[TBL] [Abstract][Full Text] [Related]
19. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.
Gabriel M; Andergassen U; Putzer D; Kroiss A; Waitz D; Von Guggenberg E; Kendler D; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):92-9. PubMed ID: 20168291
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
